Allergy Therapeutics Another six months of consistent growth

Allergy Therapeutics (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today provided a trading update for the six months ended 31 December 2020 ahead of its Half Year Results to be announced on 4 March 2020.

Financials

Reported revenues for the six months ended 31 December 2019 are expected to have grown to £50.5m (2018: £46.7m) representing 9% growth on a constant currency basis (8% on reported basis). The Group is trading in line with Board expectations. Geographically, there was growth across all major countries with the best performances in Germany, Spain, Netherlands and Switzerland. Product wise, Pollinex Quattro and Venomil continued to progress well, along with Pollinex, driven by superior technology and a robust supply chain. The Group continued to gain market share in Germany.1

The cash balance at the end of December 2019 was £39.7m (31 December 2018: £31.6m) which includes the £3.2m received in settlement of legal costs relating to the litigation with Inflamax.  

On current assumptions, the Group will be able to fund the Grass MATA MPL Phase III trial currently planned for later this year from existing resources.

Regulatory

In reference to the Grass MATA MPL Phase III trial, the Group confirms that it is on track to start the screening for the first stage of the study during summer 2020, which will be executed in the USA and the EU. The design of this study in a stepwise approach (as communicated in November 2019) incorporates the lessons learned during the analysis of the Birch MATA MPL study. The Group has now completed and submitted its final report in relation to the Birch trial and is in dialogue with the correspondent regulatory authority with regards to that product.

Finally, in reference to the development of its peanut vaccine, following the scale up process of pre-clinical materials, GMP batches for commercial development have now commenced. The Group has support from regulatory authorities to proceed to Phase I which will follow submission of the clinical trial application, including the GMP batch data package.

Manuel Llobet, CEO at Allergy Therapeutics, stated: “This represents another six months of consistent growth reflecting the quality of our platform and our team. Despite an evolving regulatory environment, we continue to perform well and we have great confidence in our commercial abilities and clinical pipeline.”

1Insight Health Data November 2019  

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
Twitter
LinkedIn
Allergy therapeutics plc

More articles like this

Allergens dominate UK food recalls, finds study

More than half of food recalls in the United Kingdom over a 5-year period were due to allergens, according to a recently released study. Allergen-related recalls increased annually until 2019, peaking at 118 before decreasing to

Allergy Therapeutics welcomes new Non-Executive Directors

Allergy Therapeutics announced the appointments of Anthony Parker and Simon Shen to its Board as Non-Executive Directors effective immediately. “I would like to welcome Anthony and Simon. Southern Fox and ZQ Capital have been long-standing and supportive shareholders of Allergy

Allergy Therapeutics updates on its clinical programmes

Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, has announced that the first subject has been dosed in the pivotal Phase III G306 trial, to evaluate the efficacy and safety of

Allergy Therapeutics appoints two Non-Executive Directors

Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, has today announced the appointments of Anthony Parker and Zheqing (Simon) Shen as Non-Executive Directors of the Company, with immediate effect. Anthony represents

Allergies and Thanksgiving

As Thanksgiving and other holiday celebrations bring people around the table, Intermountain Healthcare dietitians say it’s crucial to take food allergies into consideration when planning the big meal. “A response to an allergic reaction can be

Allergy Therapeutics appoints Martin Hopcroft as interim CFO

Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, has announced the appointment of Martin Hopcroft to the role of Interim Chief Financial Officer (CFO). Martin will report into Chief Executive

Food business operator fined for allergy breach

A food business operator based in Newcastle, England has been fined in court after serving a dish containing peanuts to a woman with a peanut allergy, resulting in her being hospitalised. According to the Food Standards

Are restaurants taking allergies seriously?

In an engaging panel held at Twickenham Stadium as part of New Food’s Food Safety Conference 2022, experts came together to debate whether food allergy regulations in restaurants are sufficient. Here’s the highlights. Are restaurant allergy

Allergy Therapeutics Subscription to raise £7 million

Allergy Therapeutics plc (LON:AGY), the fully integrated specialty pharmaceutical company specialising in allergy immunotherapy, today announces a conditional Subscription by the Subscribers, Southern Fox and ZQ Capital (acting through its affiliate SkyGem), to raise £7 million